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Dead Bugs Don’t Mutate: Susceptibility 
Issues in the Emergence of 
Bacterial Resistance
Charles W. Stratton*1
The global emergence of antibacterial resistance among
common and atypical respiratory pathogens in the last decade
necessitates the strategic application of antibacterial agents.
The use of bactericidal rather than bacteriostatic agents as
first-line therapy is recommended because the eradication of
microorganisms serves to curtail, although not avoid, the devel-
opment of bacterial resistance. Bactericidal activity is achieved
with specific classes of antimicrobial agents as well as by com-
bination therapy. Newer classes of antibacterial agents, such
as the fluoroquinolones and certain members of the macrolide/
lincosamine/streptogramin class have increased bactericidal
activity compared with traditional agents. More recently, the
ketolides (novel, semisynthetic, erythromycin-A derivatives)
have demonstrated potent bactericidal activity against key res-
piratory pathogens, including Streptococcus pneumoniae, Hae-
mophilus influenzae, Chlamydia pneumoniae, and Moraxella
catarrhalis. Moreover, the ketolides are associated with a low
potential for inducing resistance, making them promising first-
line agents for respiratory tract infections.
s the 19th century drew to a close, the work of Joseph
Lister ushered in the antimicrobial era. Lister was
among the first scientists to appreciate the implications of
Pasteur’s theory that microorganisms are involved in human
disease (1). Accordingly, he examined the inhibitory effect of
various chemicals on the growth and viability of bacteria and
directly applied the results to the practice of medicine by
using phenol (as well as heat) to sterilize surgical instru-
ments. After this early example of infection control through
antisepsis, the next step was inevitable: when chemicals with
antibacterial activity were discovered, they were soon used in
the treatment of infected patients. The ensuing clinical suc-
cess was so dramatic that these agents were hailed as miracle
drugs. By the second half of the 20th century, the practice of
medicine enjoyed almost complete dominance over infec-
tious bacteria (2).
Ironically, these same miraculous drugs now jeopardize the
miracle, as evidenced by the widespread emergence of anti-
bacterial resistance in the last decade (3–7). For example,
methicillin-resistant  Staphylococcus aureus strains have
recently appeared in community-acquired infections (8), and
Streptococcus pneumoniae strains resistant to both penicillins
and macrolides (the antibacterial agents used most frequently
for pneumococcal infections) have become prevalent through-
out the world. Indeed, rates of S. pneumoniae resistance to
penicillin now exceed 40% in many regions, and a high pro-
portion of these strains are also resistant to macrolides. More-
over, the trend is growing rapidly. Whereas 10.4% of all S.
pneumoniae isolates were resistant to penicillin and 16.5%
resistant to macrolides in 1996, these proportions rose to
14.1% and 21.9%, respectively, in 1997 (9). A more recent
susceptibility study conducted in 2000–2001 showed that
51.5% of all S. pneumoniae isolates were resistant to penicillin
and 30.0% to macrolides (10). 
The urgent need to curtail proliferation of antibacterial-
resistant bacteria has refocused attention on the proper use of
antibacterial agents. That the use of any antibacterial agent or
class of agents over time will result either in the development
of resistance to these agents or in the emergence of new patho-
genic strains that are intrinsically resistant is now widely
accepted. An example of the development of resistance is the
mutation of S. pneumoniae to produce a multidrug-resistant
strain (11). An example of a new resistant pathogenic strain is
exemplified by the emergence of Enterococcus gallinarum as
a nosocomial pathogen due to its intrinsic resistance to vanco-
mycin (12). Keeping these phenomena in check requires a
comprehensive strategy that includes, whenever possible, the
selection of antibacterial agents in dosages sufficient to be
bactericidal (13). A bactericidal effect is desired because, to
put it succinctly, dead bugs don’t mutate. In other words, if
microbial pathogens causing infection are killed by antimicro-
bial therapy, rather than inhibited, mutations that might
already exist or occur under the selective pressure of the anti-
microbial agent are less likely to be promulgated. This princi-
ple will be briefly reviewed in relation to respiratory tract
infections.
Clinical Relevance of Bacteriostatic 
versus Bactericidal Activity
All of the effects of antimicrobial agents against microbes,
including the delineation of microbial resistance, are based
upon the results of in vitro susceptibility testing. Most of these
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susceptibility tests only measure bacteriostatic activity even
though the agent being tested may have bactericidal activity.
Thus, the clinical relevance of susceptibility testing itself
could be questioned. Numerous authors have extensively
reviewed this issue over the years (14–16). These authors
point out the paucity of studies that have critically evaluated
the effectiveness of antimicrobial therapy with results of in
vitro susceptibility tests. Such critical evaluations are not eas-
ily done, as susceptibility tests do not take into account the
normal host defense mechanisms. However, the detection of
resistance is somewhat predictive of poor outcome, although
in the normal host this may be less clinically important due to
the interaction of host defenses (17,18). 
The ability of bactericidal activity to influence therapeutic
efficacy and clinical outcome has been evaluated in infections
that typically are refractory to antimicrobial therapy. These
infections include endocarditis, meningitis, osteomyelitis, and
infections in the neutropenic host. All are similar in that anti-
microbial penetration and host defense mechanisms at the site
of infection are limited. Both experimental models of infection
(19–22) and clinical studies (23–27) have shown that bacteri-
cidal activity predicts therapeutic efficacy and results in
improved clinical outcome. Bactericidal activity has been con-
sidered less important in respiratory tract infections, with the
exception being acute infectious exacerbations in cystic fibro-
sis (28). However, the relevance of pharmacokinetic and phar-
macodynamics in the selection of antibiotics for respiratory
tract infection has become increasingly recognized (29). Issues
such as drug concentration at the site of infection, bactericidal
activity, postantibiotic effect, and duration of therapy needed
to achieve these effects are now being considered when anti-
microbial agents are selected for the therapy of respiratory
tract infections (29,30). 
Although host factors may allow a bacteriostatic agent to
be used successfully in an infected patient, these factors
appear to be less able to curtail the emergence of resistance.
Resistance, as a rule, occurs more rapidly with bacteriostatic
agents such as tetracyclines, sulfonamides, and macrolides
than it does with bactericidal agents such as beta-lactams and
aminoglycosides (31–33). An example of this can be seen with
S. pneumoniae. Beta-lactam agents have been the antimicro-
bial agents of choice for the therapy of pneumococcal pneu-
monia since penicillin was first clinically introduced in the
1940s (17). Penicillin resistant strains of S. pneumoniae have
taken more than 4 decades to emerge. The emergence of mac-
rolide resistance in S. pneumoniae has been rapid in compari-
son and has even been described during treatment of
pneumococcal pneumonia (34). Bactericidal activity thus may
be useful in the therapy of respiratory tract infections as a
means to curtail, but not avoid, the emergence of resistance.  
Antibacterial Resistance Mechanisms: 
Bactericidal versus Bacteriostatic Activity
The key to resolving the problem of antibacterial resistance
lies in identifying the mechanisms that engender it (31–33).
Among the most important mechanisms are decreased ability
of antibacterials to penetrate the bacterial cell wall, active
efflux of antibacterial agents, inactivation of antibacterial
agents, destruction of antibacterial agents, alteration of anti-
bacterial target sites, development of bypass pathways around
antibacterial targets, and constitutive phenotypic variation in
bacterial physiology.
Fundamental to many of these mechanisms is mutation of
bacterial DNA. Subsequent exposure of the microorganism to
a specific agent may then select the mutant, leading to the
emergence of resistance. Some resistance mechanisms, such as
bacterial production of beta-lactamase, are inducible or can be
derepressed (35), requiring either upregulation or mutation of
genetic material. Thus, if resistance is to be suppressed, the
opportunity for bacterial upregulation or mutation of genetic
material must be minimized.
One way to minimize upregulation, mutation, or both is by
using bactericidal  rather than merely bacteriostatic agents.
Microorganisms inhibited by a bacteriostatic agent or exposed
to an insufficient concentration of a bactericidal agent remain
alive and, ipso facto, retain the potential to become resistant or
promulgate any resistance selected by the exposure to the anti-
microbial agent. An example of this principle can be seen with
the upper respiratory tract pathogen, Streptococcus pyogenes,
which to date has not developed resistance to penicillin, a bac-
tericidal agent, but has developed resistance to erythromycin, a
bacteriostatic agent (36–38). Erythromycin resistance in S.
pyogenes largely is due to upregulation of efflux (36) or to
ribosomal mutation (37). Antimicrobial agents that kill this
pathogen should be less likely to promulgate any strains hav-
ing such resistance. Another example is seen with the omp
genes of gram-negative microorganisms. These omp  genes
encode porins that are sometimes flanked by insertion
sequences. In the presence of the bacteriostatic agent, the
mobility of insertion sequence–flanking omp genes can be
attenuated and will result in disruption of the omp genes. The
reduced expression of these porins may lead to reduced uptake
of the inducer, the antibacterial agent. Specifically, insertion
sequence interruption of the ompK36 porin gene in respiratory
tract pathogen Klebsiella pneumoniae has been shown to inter-
fere in the expression of this porin gene and has resulted in
clinical failure (39). If a bactericidal agent kills a pathogen
such as Klebsiella before mutation of the porin gene, resis-
tance is less likely to develop. These two examples illustrate
the desirability of achieving bactericidal activity to curtail the
emergence of resistance.
Bactericidal Activity Achieved 
by Combination Therapy
Bactericidal activity can be achieved through the mecha-
nism of action for a single antimicrobial agent or by the use of
combination therapy, or both. Sulfamethoxazole/trimethoprim
(SMX-TMP) is an example of a combination of two agents,
each of which alone is bacteriostatic, that achieves bactericidal
activity. Sulfamethoxazole inhibits dihydropteroate synthase,PERSPECTIVES
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the bacterial enzyme that catalyzes the incorporation of p-ami-
nobenzoid acid into dihydropteroic acid, the immediate pre-
cursor of folic acid, while trimethoprim was specifically
synthesized as an inhibitor of dihydrofolate reductase (40).
SMX-TMP has long been used for the therapy of respiratory
tract infection (41) and has proven particularly useful in the
treatment of acute exacerbations of chronic bronchitis. In fact,
the World Health Organization continues to be recommend
SMX-TMP as the first-line treatment for pneumonia in chil-
dren because of its low cost and ease of dosing. Resistance to
SMX-TMP has emerged more slowly than for either agent
used alone (42). However, emergence of resistance to S. pneu-
moniae has occurred (43) and now may limit the use of SMX-
TMP in respiratory tract infections.
Combinations of antimicrobial agents are also used in the
therapy of bacterial endocarditis to achieve synergism leading
to increased bactericidal activity and improved sterilization of
infected valves. Bactericidal synergy for S. epidermidis can be
demonstrated in vitro for the combination of vancomycin,
rifampin, and gentamicin, which correlates well with the thera-
peutic results in an experimental animal model (44). In a com-
parable clinical study of patients with prosthetic valve
endocarditis caused by Staphylococcus epidermidis, 90% were
cured with a combination of vancomycin, rifampin, and/or
gentamicin, compared with only 50% cured among those
receiving vancomycin alone (45). Combination therapy for
respiratory tract infections is less well studied except for acute
respiratory tract infections occurring in cystic fibrosis patients.
For example, combination therapy for treatment of Pseudomo-
nas aeruginosa pulmonary infections in cystic fibrosis patients
achieved a cure rate of 89% if peak serum bactericidal titers
were >1:128 (28). In contrast, 100% of patients failed therapy
if their peak serum bactericidal titers were <1:16. 
Bactericidal Activity Achieved with 
Novel Bactericidal Agents
Fluoroquinolones
Other examples of the importance of bactericidal activity
are the fluoroquinolones. Studies of the bactericidal action of
the quinolones against Escherichia coli demonstrate at least
two independent and important mechanisms of action. First,
all quinolones exert bactericidal action by inhibiting topoi-
somerases. These bactericidal agents are only effective if the
bacteria are actively dividing or synthesizing proteins and
mRNA. The bactericidal activity of the quinolone nalidixic
acid, for example, is minimized by chloramphenicol, which
prevents protein synthesis, and by rifampin, which prevents
RNA synthesis. However, ciprofloxacin and ofloxacin/levof-
loxacin respond differently. Although the bactericidal action of
these fluoroquinolones against E. coli is reduced, bactericidal
action  is not entirely eliminated by chloramphenicol or
rifampin. This lack of elimination of bactericidal action sug-
gests that these agents possess a secondary bactericidal mecha-
nism of action that does not depend on the synthesis of protein
and RNA, and that may be active when the bacteria are in a
nonreplicating state (46).
To understand this secondary bactericidal effect, consider
the bacterial inducible SOS system (47). Consisting of approx-
imately 20 genes, this system repairs structural damage to
DNA caused by antibacterial agents, mainly through bypass
repair (46–50). This mechanism tends to be error prone and
often leads to mutants. Another effect of the SOS response,
activated by fluoroquinolone-induced damage to the bacterial
DNA, is the discontinuation of cell replication. The organism
can refrain from replication for only so long before it dies.
In addition to high concentrations of fluoroquinolone,
which trigger the secondary bactericidal mechanism, higher
concentrations at DNA targets also play a role in the emer-
gence of resistance because the postantibiotic effect of the flu-
oroquinolones is dependent upon concentration, time, and the
microorganism. If the concentration of fluoroquinolone
attained at the bacterial DNA targets is high enough to activate
the SOS system for a duration that exceeds the capability of
the particular microorganism to repair its DNA damage and
replicate, the microorganism dies. No postantibiotic effect
occurs, per se, since no microorganisms survive. If the fluoro-
quinolone concentration is not adequate, however, a race
occurs between cumulative damage over time and the selec-
tion of a resistant mutant.
The concentration of fluoroquinolone required for SOS-
mediated discontinuation of cell replication is expressed as a
peak concentration/minimum inhibitory concentration (MIC)
ratio and appears to require a ratio of approximately 10:1
(50,51). A rat model for Pseudomonas sepsis demonstrated
that peak concentration/MIC ratios >20:1 once per day pro-
duced significantly (p<0.5) better survival—which may result
in the selection of a mutant with altered topoisomerase—than
did regimens using the same dosage on a more fractionated
schedule (52). Dosages that led to peak concentration/MIC
ratios <10 times the MIC did not result in as high a survival
rate. Indeed, when the peak concentration/MIC ratio was <10
times the MIC, the best survival was predicted by the area
under the curve/MIC ratio, since repeated exposure to the fluo-
roquinolone causes damage cumulatively. The length of time
that fluoroquinolone levels in plasma exceeded the MIC had
no influence on survival.
The emergence of fluoroquinolone resistance with respect
to Staphylococcus aureus and P. aeruginosa has been well-
documented (53). This major problem is due to a wide variety
of fluoroquinolone-resistance mechanisms (54,55), particu-
larly the mutation of DNA gyrase (56). While this type of
resistance generally results in MICs only four- to eight-fold
higher than the susceptible isolate, recent studies have reported
the development of high-level resistance (e.g., ciprofloxacin
MIC for P. aeruginosa of 1,024 mg/L) mediated by efflux
pumps targeting multiple antibacterial agents (57,58). These
multidrug efflux pumps could be overcome by high fluoroqui-
nolone concentrations, some of which, however, would not be
clinically achievable.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 13
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A rabbit meningitis model further demonstrates how the
inability to achieve peak concentration/MIC ratios >10:1 influ-
ences the postantibiotic effect. In an in vivo study, an exposure
to ciprofloxacin at the MIC had minimal impact (59), under-
scoring the value of bactericidal activity with respect to fluoro-
quinolone therapy. The greater the activity of the
fluoroquinolone, the more likely the agent will achieve serum
or tissue levels that are >10 times the MIC, which in turn
determines the secondary bactericidal and postantibiotic
effects. Consequently, newer fluoroquinolones such as gemi-
floxacin (60) and others now under development have mark-
edly increased activity compared with traditional agents. For
example, ciprofloxacin has MICs against Streptococcus pneu-
moniae of approximately 0.5 mg/L, while gemifloxacin has
MICs of approximately 0.03 mg/L. 
An important issue associated with the use of fluoroquino-
lones in the therapy of respiratory tract infections is the fact
that fluoroquinolones also are used to treat other infections.
The use of these agents for other infections means that the
population already had been exposed to fluoroquinolones
before their widespread use in respiratory tract infections.
Exposure of normal flora in these patients to subbactericidal
concentrations of fluoroquinolones may allow resistant strains
to emerge. Cross-resistance is a well-recognized problem with
fluoroquinolones (55), and the enormous prior exposure of the
population to these agents may have created resistant strains in
the normal flora of the mucosal surfaces, skin, gastrointestinal
tract, and reproductive tract. In addition, prior exposure may
result in increasing MICs due to subtle mutations of topoi-
somerases, which then may leave the microorganism only one
step from a mutation that will produce overt resistance (55).
An example of such subtle topoisomerase mutation is seen
with fluoroquinolones such as levofloxacin, which have been
recommended and widely used for the therapy of pneumococ-
cal pneumonia when penicillin resistance to S. pneumoniae is
a problem (61). Unfortunately, the population has had consid-
erable prior exposure to earlier fluoroquinolones, which has
allowed rapid emergence of fluoroquinolone resistance in S.
pneumoniae (62). Failure of treatment of pneumococcal pneu-
monia due to resistance to levofloxacin recently has been
described (63). This example confirms the problem of cross-
resistance and further mutations resulting in increased resis-
tance and suggests that newer fluoroquinolones such as gemi-
floxacin may be less effective or even ineffective against S.
pneumoniae. 
Macrolides, Lincosamides, and Streptogramins (MLS)
Another class of antibacterials containing newly developed
bactericidal agents are the macrolides. The term macrolide was
originally applied to specific compounds produced by various
Streptomyces species containing, as part of their structure, a
macrocyclic lactone to which various deoxy sugars are
attached. These bacteriostatic compounds bind to bacterial 50S
ribosomes, inhibiting protein synthesis without a concomitant
inhibition of nucleic acid synthesis. The classification has
since been modified to include other structurally diverse
agents, such as lincosamides and streptogramins, which are
also produced by Streptomyces species and target the 50S ribo-
some. The term MLS (macrolide, lincosamide, and strepto-
gramin) has become the accepted nomenclature for this
important group of antibacterial agents—except when the
emphasis is on structural similarity, in which case the erythro-
mycin congeners (erythromycin-A, clarithromycin, and
azithromycin) are often referred to as the “true macrolides”
(64). Although antibacterial agents in the MLS class have been
largely bacteriostatic, newer members demonstrate bacteri-
cidal activity. These new agents include quinupristin/dalfopris-
tin and telithromycin.
The bactericidal mechanism of action of quinupristin/dal-
fopristin, a combination of two streptogramins, is unique (65).
Dalfopristin is an olefinic macrolactone that binds to the 50S
subunit of the prokaryotic ribosome and interferes with the
function of peptidyl transferase, thereby inactivating the donor
and acceptor sites of the ribosome. In addition, dalfopristin
triggers a conformational change in the ribosome that greatly
increases the affinity of quinupristin, a peptidic macrolactone,
which also binds to the 50S subunit of the ribosome and halts
peptide chain elongation. Consequently, protein synthesis is
not only halted transiently by either component used alone but
also halted permanently by the two components in combina-
tion, resulting in synergistic and concentration-independent
bactericidal activity against many pathogens. This binding of
both macrolactones distinguishes quinupristin/dalfopristin
from other antibiotic classes (66,67), with the attendant pro-
longation of the postantibiotic effect (68) representing a dis-
tinct advantage over older agents (69). Quinupristin/
dalfopristin is bactericidal against staphylococci and strepto-
cocci such as S. pneumoniae, generally bacteriostatic against
Enterococcus faecium, and inactive against E. faecalis (70).
Because quinupristin/dalfopristin is available only in an intra-
venous formulation, its utility for treating respiratory tract
infections is limited to hospitalized patients. Moreover, clini-
cal data on quinupristin/dalfopristin therapy of pneumococcal
pneumonia caused by macrolide resistant strains of S. pneumo-
niae is lacking. 
Ketolides: Telithromycin
Telithromycin, the first of a new class of antibacterials, the
ketolides, is approved for use in Europe and is currently being
reviewed by the U. S. Food and Drug Administration (71). The
clinical use of telithromycin in Germany, as well as safety data
presented to the Food and Drug Administration, suggests that
the toxicity and adverse reactions are similar to those of
clarithromycin. This similarity is not surprising, as the
ketolides are novel semisynthetic erythromycin-A derivatives
structurally similar to clarithromycin. The C6-hydroxyl of
erythromycin-A has been replaced by a methoxy group, as in
clarithromycin, improving acid stability. The main structural
innovation is the lack of the neutral sugar, cladinose, in posi-
tion C3. The 3-L-cladinose sugar moiety is removed, and thePERSPECTIVES
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resulting 3-hydroxy group is oxidized to a 3-keto group, which
is responsible for preventing induction of macrolide resistance
(72). Telithromycin is produced through substitution at posi-
tions 11 and 12 of the erythronolide A ring with a butyl imida-
zolyl pyridinyl side chain. The resulting C11,C12 carbamate
extension facilitates a distinctly different and more effective
interaction with domain II of the 23S rRNA than occurs with
erythromycin-A or clarithromycin (73) and is responsible for
increased activity against erythromycin-A–resistant gram-pos-
itive cocci, such as S. pneumoniae, which develop resistance
due to increased efflux (74,75). Moreover, the bactericidal
action is effective against a number of other key respiratory
pathogens, such as H. influenzae and C. pneumoniae (76–78),
other gram-negative bacilli, such as M. catarrhalis and Borde-
tella pertussis, and the intracellular pathogen Legionella pneu-
mophila (79).
Unlike erythromycin-A (which interacts with bacterial 23S
ribosomal RNA by contacts limited to hairpin 35 in domain II
of the ribosomal RNA and to the peptidyl transferase loop in
domain V49), telithromycin is not a true macrolide because the
L-cladinose moiety at position C3 has been replaced by a keto
group and by alkylaryl side chains at positions C11,C12.
Although both erythromycin-A and telithromycin bind to the
peptidyl transferase loop (the site of methylation by resistant
bacteria), telithromycin binds much more avidly to hairpin 35
than erythromycin-A. In fact, telithromycin interacts strongly
with two domains of the bacterial 23S rRNA (domains II and
V), which fold together in the tertiary 23S rRNA to form a sin-
gle drug-binding pocket (80,81). The lack of the L-cladinose
moiety, as well as the enhanced binding at domain II and V,
may explain why ketolides are associated with a low potential
for inducing resistance (82,83) and contributes to telithromy-
cin’s sustained activity against MLSB-resistant strains (in par-
ticular those with domain V modifications) (73). 
These features, in addition to the MIC and the amount of
drug delivered to the infection site, are considered strong pre-
dictors of a positive outcome (29,30). However, the population
has had enormous exposure to earlier macrolides. This expo-
sure has an influence on the normal flora of mucosal surfaces.
This influence means that resistance due to efflux or methyla-
tion of the 23S ribosome (domain V) may have already
occurred in a large number of pneumococcal isolates. Mac-
rolide-resistant strains of S. pneumoniae to date have had a
low incidence of cross-resistance to telithromycin (82,83).
However, increased efflux or other mutations might result in
resistance to ketolides. To date, only two ketolide-resistant
strains of S. pneumoniae have been identified (84) in over
10,000 pneumococcal isolates screened by the PROTEKT
study (10). The MIC of one of these isolates was 1 mg/L; the
other was 256 mg/L. Clearly, careful monitoring for ketolide
resistance by surveillance studies such as the PROTEKT study
will need to be continued.  
Conclusion
Meeting the challenge presented by the increasing num-
bers of bacterial pathogens resistant to common antibiotic
treatments will require new types of antibacterial agents. Ther-
apies that maximize bactericidal effects are important because
they reduce the development of bacterial resistance mecha-
nisms. Therefore, the use of bactericidal agents such as
telithromycin for therapy of respiratory tract infections may
well ensure that the antibacterial era endures long into the 21st
century. However, careful monitoring of resistance will be
needed to ensure that this agent remains active against com-
mon pathogens. 
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